CNV

(redirected from Choroidal Neovascularization)
Also found in: Medical.
AcronymDefinition
CNVCommunication Non Violente (French: Nonviolent Communication)
CNVChoroidal Neovascularization (eye disorder)
CNVCopy Number Variation
CNVContingent Negative Variation
CNVComisión Nacional de Valores (Argentina)
CNVConseil National des Villes (French: National Council of Cities)
CNVConverter
CNVConvertible
CNVConveyor
CNVChristelijk Nationaal Vakverbond
CNVCercle Nautique Verdunois (French rowing club)
CNVClub Nautique de Viry-Châtillon (French: Nautical Club of Viry-Chatillon; Viry-Chatillon, France)
CNVContinuous Negative Variation
CNVCastelton (Amtrak station code; Castleton, VT)
CNVCould Not Verify
CNVChief of Navy
CNVContinuous Normal Voltage
CNVCrypto Net Variable
References in periodicals archive ?
Eylea has also been approved for the treatment of myopic choroidal neovascularization.
They report that OCTA provides data important both for understanding the pathogenesis of MacTel 2 and for patient follow-up, allowing clear observation of changes in the deep vascular plexus in early disease and choroidal neovascularization in later disease stages, unlike fundus fluorescein angiography.
The visual outcomes following PCV are generally better compared with choroidal neovascularization (CNV) following AMD.
Wet AMD is caused by growth of abnormal blood vessels, also known as choroidal neovascularization or ocular angiogenesis, under the macula.
GlobalData's clinical trial report, "Choroidal Neovascularization Global Clinical Trials Review, H1, 2016" provides an overview of Choroidal Neovascularization clinical trials scenario.
The Array LaserLink device is indicated for the variety of ophthalmic uses specified for the laser to which it is attached, including diabetic retinopathy, choroidal neovascularization, branch retinal vein occlusion, retinal tears and detachments.
Biopharmaceutical company Regeneron Pharmaceuticals (NASDAQ:REGN) revealed on Friday that ti has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), an eye disease associated with high degrees of myopia (near-sightedness).
Bayer HealthCare has received European approval for EYLEA (aflibercept) Injection for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), an eye disease associated with high degrees of myopia (near-sightedness) and frequently affects people of working age.
Specifically designed for the eye and proven to save sight, ranibizumab is indicated for the treatment of neovascular wet age-related macular degeneration (wet AMD), visual impairment due to DME and due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO); and visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
Their topics include principles of optical coherence tomography-angiography, solving the practical problems of Angio-OCT, the analysis and interpretation of a pathological Angio-OCT, Angio-OCT of choroidal neovascularization in age-related macular degeneration, advantages and disadvantages of fluorescein angiography and Angio-OCT, and future ultra-high-speed swept-source OCT technology and OCT-angiography.
The trial is designed to assess the safety and tolerability of topical ocular PAN-90806 at three dosage strengths in patients with active, subfoveal choroidal neovascularization associated with neovascular AMD.